Dubai, United Arab Emirates: Boehringer Ingelheim - one of the world’s leading pharmaceutical companies has announced positive top-line results from the EMPEROR-Reduced Phase III trial in adults with chronic heart failure with reduced ejection fraction. The trial met its primary endpoint, demonstrating superiority empagliflozin (10mg) versus placebo on top of standard of care, in reducing the risk for cardiovascular death or hospitalisation due to heart failure.

Many Middle Eastern countries have observed increases in the prevalence of risk factors for heart failure, which is seen to develop in their populations at least 10 years earlier than in Western counterpart populations[1]. The risk factors include diabetes mellitus, obesity, and hypertension[2]. Heart failure with reduced ejection fraction occurs when the heart muscle does not contract effectively and pumps out less blood to the body compared to a normally functioning heart[3]. Symptoms associated with heart failure include breathlessness and fatigue, which can severely impact upon quality of life[4]. There remains a high unmet need in the treatment of heart failure, as approximately 50 percent of all those diagnosed with the condition die within five years[5].

The EMPEROR-Reduced clinical trials form part of the EMPOWER clinical programme, one of the broadest, most comprehensive trials of any SGLT2 inhibitor, exploring the impact of treatments across cardio-renal-metabolic conditions. Building on findings from EMPA-REG OUTCOME®, these positive results demonstrate that empagliflozin has the potential to fill unmet therapeutic needs for people with this highly prevalent condition.

Full results from the EMPEROR-Reduced trial will be presented in a hot line session at the European Society of Cardiology (ESC) congress 2020, which is being held 29 August. A second trial, EMPEROR-Preserved, the results of which are expected in 2021, will explore the effect of empagliflozin on cardiovascular death and hospitalisation for heart failure in adults with heart failure with preserved ejection fraction[6] - an area of high unmet need as there are currently no treatment options available for people with this form of heart failure[7].

[1] Al-Shamiri, Mostafa Q. “Heart failure in the Middle East.” Current cardiology reviews vol. 9,2 (2013): 174-8. doi:10.2174/1573403x11309020009

[2] Al-Shamiri, Mostafa Q. “Heart failure in the Middle East.” Current cardiology reviews vol. 9,2 (2013): 174-8. doi:10.2174/1573403x11309020009

[3] American Heart Association. Ejection Fraction Heart Failure Measurement. Available at: https://www.heart.org/en/health-topics/heart-failure/diagnosing-heart-failure/ejection-fraction-heart-failure-measurement. Accessed July 2020.

[4] American Heart Association. Warning Signs of Heart Failure. Available at: https://www.heart.org/en/health-topics/heart-failure/warning-signs-of-heart-failure. Accessed July 2020.

[5] Ponikowski P, Anker SD, AlHabib KF. Heart Failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4–25.

[6] ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved). Available at: https://clinicaltrials.gov/ct2/show/NCT03057951. Accessed July 2020.

[7] Harper A, Patel H, Lyon A. Heart failure with preserved ejection fraction. Clin Med (Lond). 2018;18(Suppl 2): s24–s29.

Send us your press releases to pressrelease.zawya@refinitiv.com

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.